Buformin hydrochloride

TargetMol
Product Code: TAR-T20029
Supplier: TargetMol
CodeSizePrice
TAR-T20029-1mL1 mL * 10 mM (in DMSO)£107.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T20029-50mg50mg£124.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T20029-100mg100mg£149.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T20029-200mg200mg£197.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
TAR-T20029-500mg500mg£325.00
Special offer! Add £1 to your order to get a TargetMol CCK-8 Kit. Read more here.
Quantity:
Prices exclude any Taxes / VAT

Overview

Regulatory Status: RUO
Shipping:
cool pack
Storage:
-20℃

Images

1 / 1

Further Information

Bioactivity:
Buformin hydrochloride is a potent AMPK activator,an oral antidiabetic drug of the biguanide class. Buformin delays the absorption of glucose from the gastrointestinal tract increases insulin sensitivity and glucose uptake into cells and inhibits synthesis of glucose by the liver. Biguanides may antagonize the action of glucagon, thus reducing fasting glucose levels.
CAS:
1190-53-0
Formula:
C6H16ClN5
Molecular Weight:
193.68
Pathway:
Chromatin/Epigenetic; PI3K/Akt/mTOR signaling
Purity:
0.9783
SMILES:
Cl.CCCCNC(=N)NC(N)=N
Target:
AMPK

References

1. Amanda B Parris, et al. Buformin hydrochloride Inhibits the Stemness of erbB-2-overexpressing Breast Cancer Cells and Premalignant Mammary Tissues of MMTV-erbB-2 Transgenic Mice. J Exp Clin Cancer Res 2. Jing Li, et al. Buformin hydrochloride Suppresses Proliferation and Invasion via AMPK/S6 Pathway in Cervical Cancer and Synergizes With Paclitaxel. Cancer Biol Ther. 2018 Jun 3;19(6):507-517. 3. Gutsche H, Blumenbach L, Losert W, Wiemann H. [Concentration of 14C-1-butylbiguanide in plasma of diabetic patients and its elimination after administration of a new Galenical formulation (author's transl)]. Arzneimittelforschung. 1976;26(6):1227-9. German. PubMed PMID: 989423. 4. Beckmann VR. [Reduction of serum triglycerides with a combined application of butylbiguanide and clofibrate in animal experiments]. Arzneimittelforschung. 1975 May;25(5):775-6. German. PubMed PMID: 1242321.